Ulf Wiinberg - Agenus Director
AJ81 Stock | EUR 7.80 0.00 0.00% |
Director
Mr. Ulf Wiinberg is an Independent Director of Agenus Inc. Mr. Wiinberg has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck AS from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the worlds largest researchdriven pharmaceutical companies that was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East President of Consumer Healthcare Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP, a Londonbased drug development company, Hansa Medical AB, a Swedish biopharmaceutical company, and Alfa Laval AB, a Swedish industrial company. Mr. Wiinberg brings to our Board years of experience in the biotechnology, pharmaceutical and healthcare industries internationally. since 2016.
Age | 59 |
Tenure | 8 years |
Phone | 781 674 4400 |
Web | https://www.agenusbio.com |
Ulf Wiinberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ulf Wiinberg against Agenus stock is an integral part of due diligence when investing in Agenus. Ulf Wiinberg insider activity provides valuable insight into whether Agenus is net buyers or sellers over its current business cycle. Note, Agenus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Agenus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ulf Wiinberg over two weeks ago Acquisition by Ulf Wiinberg of 38635 shares of Agenus subject to Rule 16b-3 | ||
Ulf Wiinberg over three months ago Purchase by Ulf Wiinberg of 25000 shares of Agenus | ||
Ulf Wiinberg over six months ago Acquisition by Ulf Wiinberg of 18001 shares of Agenus subject to Rule 16b-3 | ||
Ulf Wiinberg over six months ago Acquisition by Ulf Wiinberg of 16018 shares of Agenus subject to Rule 16b-3 |
Agenus Management Efficiency
The company has return on total asset (ROA) of (0.2577) % which means that it has lost $0.2577 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (18.903) %, meaning that it generated substantial loss on money invested by shareholders. Agenus' management efficiency ratios could be used to measure how well Agenus manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Ross Levinsohn | NorAm Drilling AS | 54 | |
David Smith | Superior Plus Corp | 59 | |
Peter Murphy | NorAm Drilling AS | 55 | |
Randall Findlay | Superior Plus Corp | 67 | |
Douglas Harrison | Superior Plus Corp | 58 | |
Walentin Mirosh | Superior Plus Corp | 71 | |
Laura Walker | NorAm Drilling AS | 60 | |
Michael Kreger | NorAm Drilling AS | 33 | |
James Arestia | NorAm Drilling AS | N/A | |
Mary Jordan | Superior Plus Corp | 58 | |
Patrick Gottschalk | Superior Plus Corp | 54 | |
Peter Kern | NorAm Drilling AS | 50 | |
Robert Engbloom | Superior Plus Corp | 64 | |
Richard Bradeen | Superior Plus Corp | 61 | |
Eugene Bissell | Superior Plus Corp | 64 | |
Catherine Best | Superior Plus Corp | 64 | |
Craig Jacobson | NorAm Drilling AS | 65 |
Management Performance
Return On Equity | -18.9 | |||
Return On Asset | -0.26 |
Agenus Inc Leadership Team
Elected by the shareholders, the Agenus' board of directors comprises two types of representatives: Agenus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agenus. The board's role is to monitor Agenus' management team and ensure that shareholders' interests are well served. Agenus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agenus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Stein, Chief Scientific Officer | ||
James Gorman, Vice President - Strategic Planning and Portfolio Management | ||
Ozer Baysal, Chief Business Officer | ||
Regina Grebla, VP Communications | ||
Shalini Sharp, Director | ||
John Castle, Head Bioinformatics | ||
Wadih Jordan, Independent Director | ||
Christine Klaskin, Principal Financial Officer, Principal Accounting Officer, Vice President - Finance | ||
Jennifer Buell, Pres Therapeutics | ||
Don Vidic, Vice President Head of Commercial | ||
Brian Corvese, Independent Director | ||
Karen Valentine, Vice President Chief Compliance Officer, General Counsel, Secretary | ||
Evan Ballantyne, CFO | ||
Timothy Wright, Lead Independent Director | ||
Christian Cortis, Chief Strategy Officer and Head of Finance | ||
Julie DeSander, Chief Officer | ||
Ulf Wiinberg, Director | ||
Alexander Duncan, CTO and Head - Research | ||
Tracy Clemente, Chief Officer | ||
Allison JeynesEllis, Director | ||
Garo Armen, Chairman of the Board, CEO | ||
JeanMarie Cuillerot, Chief Medical Officer | ||
Andrea Rabney, IR Contact Officer | ||
Craig Winter, Chief Officer | ||
Robin JD, Chief Officer | ||
Shahzad Malik, Independent Director | ||
Evan Kearns, Vice President General Counsel, Secretary |
Agenus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agenus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -18.9 | |||
Return On Asset | -0.26 | |||
Profit Margin | (2.39) % | |||
Operating Margin | (1.99) % | |||
Current Valuation | 646 M | |||
Shares Outstanding | 304.81 M | |||
Shares Owned By Insiders | 8.96 % | |||
Shares Owned By Institutions | 65.26 % | |||
Price To Earning | (3.13) X | |||
Price To Book | 181.30 X |
Pair Trading with Agenus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agenus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agenus will appreciate offsetting losses from the drop in the long position's value.Moving against Agenus Stock
0.7 | TM2 | Sydbank A/S | PairCorr |
0.69 | 0QF | Moderna | PairCorr |
0.64 | SON1 | Sony Group Corp | PairCorr |
0.64 | BFP | BBVA Banco Frances | PairCorr |
0.56 | MIZ | Mizuno | PairCorr |
The ability to find closely correlated positions to Agenus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agenus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agenus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agenus Inc to buy it.
The correlation of Agenus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agenus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agenus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agenus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the Agenus Inc information on this page should be used as a complementary analysis to other Agenus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Agenus Stock analysis
When running Agenus' price analysis, check to measure Agenus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agenus is operating at the current time. Most of Agenus' value examination focuses on studying past and present price action to predict the probability of Agenus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agenus' price. Additionally, you may evaluate how the addition of Agenus to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Valuation Check real value of public entities based on technical and fundamental data |